Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100102507> ?p ?o ?g. }
- W3100102507 endingPage "3441" @default.
- W3100102507 startingPage "3441" @default.
- W3100102507 abstract "Special AT-rich sequence-binding protein 2 (SATB2) is a transcription factor expressed by colonic cryptic epithelium and epithelial neoplasms of the lower gastrointestinal (GI) tract, as well as by small bowel adenocarcinomas (SBAs), though at a lower rate. Nevertheless, up to now, only small SBA series, often including a very limited number of Crohn’s disease-associated SBAs (CrD-SBAs) and celiac disease-associated SBAs (CD-SBA), have been investigated for SATB2 expression. We evaluated the expression of SATB2 and other GI phenotypic markers (cytokeratin (CK) 7 and CK20, caudal type homeobox 2 (CDX2) and alpha-methylacyl-CoA racemase (AMACR)), as well as mismatch repair (MMR) proteins, in 100 SBAs, encompassing 34 CrD-SBAs, 28 CD-SBAs and 38 sporadic cases (Spo-SBAs). Any mutual association and correlation with other clinico-pathologic features, including patient prognosis, were searched. Twenty (20%) SATB2-positive SBAs (4 CrD-SBAs, 7 CD-SBAs and 9 Spo-SBAs) were identified. The prevalence of SATB2 positivity was lower in CrD-SBA (12%) in comparison with both CD-SBAs (25%) and Spo-SBAs (24%). Interestingly, six SBAs (two CD-SBAs and four Spo-SBAs) displayed a full colorectal carcinoma (CRC)-like immunoprofile (CK7−/CK20+/CDX2+/AMACR+/SATB2+); none of them was a CrD-SBA. No association between SATB2 expression and MMR status was observed. Although SATB2-positive SBA patients showed a more favorable outcome in comparison with SATB2-negative ones, the difference did not reach statistical significance. When cancers were stratified according to CK7/CK20 expression patterns, we found that CK7−/CK20- SBAs were enriched with MMR-deficient cases (71%) and patients with CK7−/CK20− or CK7−/CK20+ SBAs had a significantly better survival rate compared to those with CK7+/CK20− or CK7+/CK20+ cancers (p = 0.002). To conclude, we identified a small (6%) subset of SBAs featuring a full CRC-like immunoprofile, representing a potential diagnostic pitfall in attempts to identify the site of origin of neoplasms of unknown primary site. In contrast with data on colorectal carcinoma, SATB2 expression is not associated with MMR status in SBAs. CK patterns influence patient survival, as CK7−/CK20− cancers show better prognosis, a behavior possibly due to the high rate of MMR-deficient SBAs within this subgroup." @default.
- W3100102507 created "2020-11-23" @default.
- W3100102507 creator A5004158910 @default.
- W3100102507 creator A5004814157 @default.
- W3100102507 creator A5005055630 @default.
- W3100102507 creator A5005608989 @default.
- W3100102507 creator A5005904384 @default.
- W3100102507 creator A5006430726 @default.
- W3100102507 creator A5009993019 @default.
- W3100102507 creator A5013641235 @default.
- W3100102507 creator A5013643615 @default.
- W3100102507 creator A5021643347 @default.
- W3100102507 creator A5026242246 @default.
- W3100102507 creator A5027344325 @default.
- W3100102507 creator A5027922170 @default.
- W3100102507 creator A5031684570 @default.
- W3100102507 creator A5046111364 @default.
- W3100102507 creator A5048401511 @default.
- W3100102507 creator A5057206298 @default.
- W3100102507 creator A5057940142 @default.
- W3100102507 creator A5059068187 @default.
- W3100102507 creator A5063169537 @default.
- W3100102507 creator A5064056057 @default.
- W3100102507 creator A5064073455 @default.
- W3100102507 creator A5065961744 @default.
- W3100102507 creator A5067892973 @default.
- W3100102507 creator A5071325068 @default.
- W3100102507 creator A5085146789 @default.
- W3100102507 creator A5088008401 @default.
- W3100102507 creator A5088165071 @default.
- W3100102507 date "2020-11-19" @default.
- W3100102507 modified "2023-09-28" @default.
- W3100102507 title "Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall" @default.
- W3100102507 cites W1569314672 @default.
- W3100102507 cites W1977864526 @default.
- W3100102507 cites W1990617748 @default.
- W3100102507 cites W2006473247 @default.
- W3100102507 cites W2019374657 @default.
- W3100102507 cites W2023837818 @default.
- W3100102507 cites W2038188490 @default.
- W3100102507 cites W2039406513 @default.
- W3100102507 cites W2053372485 @default.
- W3100102507 cites W2069104763 @default.
- W3100102507 cites W2076863148 @default.
- W3100102507 cites W2105244370 @default.
- W3100102507 cites W2109540605 @default.
- W3100102507 cites W2114804303 @default.
- W3100102507 cites W2124091806 @default.
- W3100102507 cites W2378601153 @default.
- W3100102507 cites W2460709649 @default.
- W3100102507 cites W2523706394 @default.
- W3100102507 cites W2530876382 @default.
- W3100102507 cites W2590867271 @default.
- W3100102507 cites W2625048728 @default.
- W3100102507 cites W2733153381 @default.
- W3100102507 cites W2740618228 @default.
- W3100102507 cites W2761460841 @default.
- W3100102507 cites W2791209543 @default.
- W3100102507 cites W2884785610 @default.
- W3100102507 cites W2898571352 @default.
- W3100102507 cites W2901690567 @default.
- W3100102507 cites W2912623612 @default.
- W3100102507 cites W2939134067 @default.
- W3100102507 cites W2952276474 @default.
- W3100102507 cites W2967834469 @default.
- W3100102507 cites W2971594300 @default.
- W3100102507 cites W2971749607 @default.
- W3100102507 cites W2999134910 @default.
- W3100102507 cites W3006486601 @default.
- W3100102507 cites W3012769951 @default.
- W3100102507 cites W3042701674 @default.
- W3100102507 cites W3047267448 @default.
- W3100102507 cites W3084946487 @default.
- W3100102507 cites W4210972014 @default.
- W3100102507 doi "https://doi.org/10.3390/cancers12113441" @default.
- W3100102507 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7699330" @default.
- W3100102507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33228145" @default.
- W3100102507 hasPublicationYear "2020" @default.
- W3100102507 type Work @default.
- W3100102507 sameAs 3100102507 @default.
- W3100102507 citedByCount "7" @default.
- W3100102507 countsByYear W31001025072022 @default.
- W3100102507 countsByYear W31001025072023 @default.
- W3100102507 crossrefType "journal-article" @default.
- W3100102507 hasAuthorship W3100102507A5004158910 @default.
- W3100102507 hasAuthorship W3100102507A5004814157 @default.
- W3100102507 hasAuthorship W3100102507A5005055630 @default.
- W3100102507 hasAuthorship W3100102507A5005608989 @default.
- W3100102507 hasAuthorship W3100102507A5005904384 @default.
- W3100102507 hasAuthorship W3100102507A5006430726 @default.
- W3100102507 hasAuthorship W3100102507A5009993019 @default.
- W3100102507 hasAuthorship W3100102507A5013641235 @default.
- W3100102507 hasAuthorship W3100102507A5013643615 @default.
- W3100102507 hasAuthorship W3100102507A5021643347 @default.
- W3100102507 hasAuthorship W3100102507A5026242246 @default.
- W3100102507 hasAuthorship W3100102507A5027344325 @default.
- W3100102507 hasAuthorship W3100102507A5027922170 @default.
- W3100102507 hasAuthorship W3100102507A5031684570 @default.